Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (50,111)	$ (32,024)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	257	32
Research and development license expense	1,250	5,500
Stock-based compensation	5,329	3,594
Other	194
Changes in operating assets and liabilities:
Prepaid expenses and other assets	271	(4,184)
Accounts payable	2,544	1,872
Accrued expenses and other liabilities	(538)	3,183
Due to related party		(8)
Net cash used in operating activities	(40,804)	(22,035)
Cash flows from investing activities
Purchase of research and development license	(3,000)
Purchase of property, plant and equipment	(8,427)	(534)
Net cash used in investing activities	(11,427)	(534)
Cash flows from financing activities
Payment of shelf registration costs	(151)
ESPP contributions	277
Other	(368)
Net cash used in financing activities	(242)
Net decrease in cash, cash equivalents and restricted cash	(52,473)	(22,569)
Cash, cash equivalents and restricted cash at the beginning of the period	151,740	251,253
Cash, cash equivalents and restricted cash at the end of the period	99,267	228,684
Cash and cash equivalents	96,630	228,684
Restricted cash	2,637
Supplemental disclosure of cash flow information:
Cash paid for interest	419
Supplemental disclosure of noncash investing and financing activities:
Property, plant and equipment in accounts payable and accrued expenses	4,513	1,101
Acquisition of property, plant and equipment funded by landlord		607
Deferred offering costs not yet paid	21	128
Purchase of research and development license not yet paid	$ 1,250	$ 5,500